263 related articles for article (PubMed ID: 25261048)
1. Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study.
Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
Urology; 2015 Jan; 85(1):92-100. PubMed ID: 25261048
[TBL] [Abstract][Full Text] [Related]
2. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
Ann Intern Med; 2013 May; 158(10):709-17. PubMed ID: 23689764
[TBL] [Abstract][Full Text] [Related]
3. Comorbidity and competing risks for mortality in men with prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
Cancer; 2011 Oct; 117(20):4642-50. PubMed ID: 21480201
[TBL] [Abstract][Full Text] [Related]
4. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
5. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
[TBL] [Abstract][Full Text] [Related]
6. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
[TBL] [Abstract][Full Text] [Related]
7. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
9. Impact of comorbidity on survival among men with localized prostate cancer.
Albertsen PC; Moore DF; Shih W; Lin Y; Li H; Lu-Yao GL
J Clin Oncol; 2011 Apr; 29(10):1335-41. PubMed ID: 21357791
[TBL] [Abstract][Full Text] [Related]
10. Competing Risks of Mortality among Men with Biochemical Recurrence after Radical Prostatectomy.
Daskivich TJ; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen Z; Terris MK; Freedland SJ
J Urol; 2020 Sep; 204(3):511-517. PubMed ID: 32243242
[TBL] [Abstract][Full Text] [Related]
11. Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study.
Thorstenson A; Garmo H; Adolfsson J; Bratt O
J Urol; 2017 Jan; 197(1):61-66. PubMed ID: 27328367
[TBL] [Abstract][Full Text] [Related]
12. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Dec; 120(23):3642-50. PubMed ID: 25042117
[TBL] [Abstract][Full Text] [Related]
13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
14. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT).
Wilt TJ; Vo TN; Langsetmo L; Dahm P; Wheeler T; Aronson WJ; Cooperberg MR; Taylor BC; Brawer MK
Eur Urol; 2020 Jun; 77(6):713-724. PubMed ID: 32089359
[TBL] [Abstract][Full Text] [Related]
15. Use of Age and Medical Comorbidity to Assess Long-term Other-cause Mortality Risk in a Cohort of Men Undergoing Prostate Biopsy at an Academic Medical Center.
Kominsky HD; Bashline M; Eun D; Pontari MA; Mydlo JH; Reese AC
Urology; 2017 Feb; 100():169-174. PubMed ID: 27639788
[TBL] [Abstract][Full Text] [Related]
16. Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study.
Hoffman RM; Koyama T; Albertsen PC; Barry MJ; Daskivich TJ; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Potosky AL; Penson DF
J Gen Intern Med; 2015 Jul; 30(7):924-34. PubMed ID: 25678374
[TBL] [Abstract][Full Text] [Related]
17. The risk of prostate cancer mortality and cardiovascular mortality of nonmetastatic prostate cancer patients: A population-based retrospective cohort study.
Matthes KL; Pestoni G; Korol D; Van Hemelrijck M; Rohrmann S
Urol Oncol; 2018 Jun; 36(6):309.e15-309.e23. PubMed ID: 29576269
[TBL] [Abstract][Full Text] [Related]
18. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
19. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
